via
X
2
Recherche par hashtag
INmune Bio ($INMB) just built its international commercial launchpad without spending like it’s building one.
The biotech signed a Master Services Agreement with Uniphar to handle access, distribution and commercialization of Ebstrocel, its cell therapy for RDEB, a rare and painful genetic skin disease. The first phase focuses on named-patient access in selected European and MENA markets, which lets physicians request the drug for individual patients before local approval, where law allows.
For investors, the key word is capital efficiency. Rather than building sales, logistics and market access teams country by country, INmune Bio is plugging into Uniphar’s platform, which spans 160 countries and covers storage, shipping, regulatory feasibility, pharmacovigilance and order-to-cash. That keeps fixed costs low and lets the company scale only as markets open up, which matters for a small-cap biotech where cash runway is always part of the story.
It also hints at an early revenue pathway before formal approvals. Still, Ebstrocel is investigational, and named-patient access is typically limited in scale, so this is groundwork rather than a revenue driver today. The bigger catalysts are ahead: a UK MHRA filing planned for 2026, an EU EMA filing in 2027, and a Phase 2b/3 program for its Alzheimer’s candidate XPro1595.
Does a capital-light commercial model make INMB a more attractive small-cap biotech, or does the real test come with regulatory approval? 🤔
#INMB #Biotech #StockMarket #Investing #SmallCap #HealthcareStocks
The biotech signed a Master Services Agreement with Uniphar to handle access, distribution and commercialization of Ebstrocel, its cell therapy for RDEB, a rare and painful genetic skin disease. The first phase focuses on named-patient access in selected European and MENA markets, which lets physicians request the drug for individual patients before local approval, where law allows.
For investors, the key word is capital efficiency. Rather than building sales, logistics and market access teams country by country, INmune Bio is plugging into Uniphar’s platform, which spans 160 countries and covers storage, shipping, regulatory feasibility, pharmacovigilance and order-to-cash. That keeps fixed costs low and lets the company scale only as markets open up, which matters for a small-cap biotech where cash runway is always part of the story.
It also hints at an early revenue pathway before formal approvals. Still, Ebstrocel is investigational, and named-patient access is typically limited in scale, so this is groundwork rather than a revenue driver today. The bigger catalysts are ahead: a UK MHRA filing planned for 2026, an EU EMA filing in 2027, and a Phase 2b/3 program for its Alzheimer’s candidate XPro1595.
Does a capital-light commercial model make INMB a more attractive small-cap biotech, or does the real test come with regulatory approval? 🤔
#INMB #Biotech #StockMarket #Investing #SmallCap #HealthcareStocks
1
via
X
Samplix, a Danish #BioTech company developing droplet #microfluidics technology for functional single-cell analysis, has announced a €25 million first closing of a #financing round. 🇩🇰 🧬 🔬
https://t.co/BNkRc8UyRm
https://t.co/BNkRc8UyRm
1
Moderna’s stock just gave back a big chunk of its August rally, and it happened before the full data was even officially out.
Details from the melanoma vaccine trial leaked ahead of Saturday’s presentation in Madrid, and the stock fell as much as 26% on Thursday before closing down about 17%. That’s more than $17 billion in market value gone in a single session, and the biggest intraday drop in the company’s history.
Here’s the odd part: the results themselves are still good. The personalized vaccine, combined with Keytruda, cut the risk of the cancer returning or causing death by 42%. The problem was the run-up. Moderna had nearly quadrupled since mid-August, after jumping 177% in a single day when the trial first met its goals, so expectations were sky-high. When the real number landed at the lower end of what investors hoped for, the selling started.
Merck, the vaccine’s partner, barely flinched, since for them it’s an add-on rather than the whole story. Eli Lilly, J&J and Pfizer actually rose, and the broader biotech ETFs were only slightly lower, so this was mostly a Moderna story rather than a sector sell-off.
All eyes are now on Saturday’s full data, especially how lower-risk patients responded.
#Moderna #MRNA #Merck #Biotech #StockMarket
Details from the melanoma vaccine trial leaked ahead of Saturday’s presentation in Madrid, and the stock fell as much as 26% on Thursday before closing down about 17%. That’s more than $17 billion in market value gone in a single session, and the biggest intraday drop in the company’s history.
Here’s the odd part: the results themselves are still good. The personalized vaccine, combined with Keytruda, cut the risk of the cancer returning or causing death by 42%. The problem was the run-up. Moderna had nearly quadrupled since mid-August, after jumping 177% in a single day when the trial first met its goals, so expectations were sky-high. When the real number landed at the lower end of what investors hoped for, the selling started.
Merck, the vaccine’s partner, barely flinched, since for them it’s an add-on rather than the whole story. Eli Lilly, J&J and Pfizer actually rose, and the broader biotech ETFs were only slightly lower, so this was mostly a Moderna story rather than a sector sell-off.
All eyes are now on Saturday’s full data, especially how lower-risk patients responded.
#Moderna #MRNA #Merck #Biotech #StockMarket
2
Moderna and Merck’s personalized cancer vaccine just posted its numbers, and they’re good, though not quite what Wall Street hoped for.
In a late-stage trial in advanced melanoma, adding the vaccine to Keytruda cut the risk of the cancer returning or causing death by 42% compared to Keytruda alone. It also lowered the risk of the disease spreading to distant organs by 38%, with side effects that were mostly mild, mainly fever and injection-site pain.
For a cancer where a third or more of patients still relapse or die within five years, doctors involved in the study called it a real step forward. One investigator said researchers had tried for years to improve on Keytruda and never managed it until now.
The market was less impressed. Investors had been hoping for 40-50%, and the result landed a little below the 44% seen in an earlier, smaller trial. Moderna’s stock dropped sharply on the news, which some analysts called a classic “sell the news” move.
The bigger question is whether this approach works beyond melanoma. Studies in lung, bladder and kidney cancer are already underway.
Is a result like this a breakthrough in the making, or does the science still have more to prove? 🤔
#Moderna #Merck #CancerResearch #Biotech
In a late-stage trial in advanced melanoma, adding the vaccine to Keytruda cut the risk of the cancer returning or causing death by 42% compared to Keytruda alone. It also lowered the risk of the disease spreading to distant organs by 38%, with side effects that were mostly mild, mainly fever and injection-site pain.
For a cancer where a third or more of patients still relapse or die within five years, doctors involved in the study called it a real step forward. One investigator said researchers had tried for years to improve on Keytruda and never managed it until now.
The market was less impressed. Investors had been hoping for 40-50%, and the result landed a little below the 44% seen in an earlier, smaller trial. Moderna’s stock dropped sharply on the news, which some analysts called a classic “sell the news” move.
The bigger question is whether this approach works beyond melanoma. Studies in lung, bladder and kidney cancer are already underway.
Is a result like this a breakthrough in the making, or does the science still have more to prove? 🤔
#Moderna #Merck #CancerResearch #Biotech
3